Patents : |  |
| US Patent No. | Title |
| 7524832 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts
|
| 7550262 | PTPN11 (SHP-2) mutations and cancer
|
| 7550432 | Recombinant fusion proteins to growth hormone and serum albumin
|
| 7553816 | p-amidobenzylethers in drug delivery agents
|
| 7553936 | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
|
| 7556809 | Active antiangiogenic therapy
|
| 7563787 | Substituted pyrazole compounds
|
| 7565205 | Treating a tumor or the like with electric fields at different orientations
|
| 7565206 | Treating a tumor or the like with electric fields at different orientations
|
| 7569384 | Albumin fusion proteins
|
| 7569566 | Inhibitors of tyrosine kinases
|
| 7550140 | Antibody to the human OX40 receptor
|
| 7547766 | Anti-tango294 antibodies and uses thereof
|
| 7544681 | Conjugated psychotropic drugs and uses thereof
|
| 7524872 | Method and composition for treating cancer using cellular organelle crystallizing agents
|
| 7531310 | Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
|
| 7531501 | Method of treating endothelial injury
|
| 7531553 | Heterocyclic compounds and methods of use
|
| 7534428 | Antibodies to tumor necrosis factor receptors 6.alpha. and 6.beta.
|
| 7537887 | Net, a transcription factor of the TCF family, as regulator of angiogenic factor expression
|
| 7538252 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
|
| 7541342 | Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents
|
| 7541434 | Polypeptide for a TRP channel family member, TRP-PLIK2, and splice variants
|
| 7541441 | Antibodies that specifically bind to TL5
|
| 7572821 | Compounds for the treatment of proliferative disorders
|
| 7575879 | Polypeptides homologous to VEGF and BMP1
|
| 7598348 | Adiponectin receptor variant, AdipoR2v2
|
| 7598355 | Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto
|
| 7599745 | Treating a tumor or the like with an electric field
|
| 7601344 | Host cells obtained by introducing and expressing VHL gene in cancer cells or embryonic stem cells
|
| 7601359 | Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins
|
| 7604799 | EphA4 Antibodies
|
| 7605236 | Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
| 7608260 | Stabilized immunoglobulins
|
| 7608635 | Pyrazole compounds that modulate HSP90 activity
|
| 7611879 | 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor
|
| 7598239 | Conjugated psychotropic drugs and uses thereof
|
| 7597886 | Tumor necrosis factor-gamma
|
| 7597884 | Hyperglycosylated polypeptide variants and methods of use
|
| 7576130 | Dihydroxyl compounds and compositions for cholesterol management and related uses
|
| 7576177 | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
|
| 7579503 | BIS (thio-hydrazide amide) salts for treatment of cancers
|
| 7582614 | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
|
| 7582726 | VEGF receptor antagonists
|
| 7585997 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
|
| 7589190 | Potent LNA oligonucleotides for the inhibition of HIF-1A expression
|
| 7592010 | Albumin fusion proteins
|
| 7592422 | Modified plasminogen activator inhibitor type-1 and methods based thereon
|
| 7595038 | Methods of treatment using antibodies to follistatin-3
|
| 7619006 | Conjugated psychotropic drugs and uses thereof
|
